Video

Clinical Implications of BTK Inhibitors in CLL

Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.

Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
David C. Fisher, MD
Related Content
Chronic Lymphocytic Leukemia
November 13th 2024

Piecing Together the Proper BTK Usage in CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

OncLive's Top 5 Stories of the Week in Oncology
November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

HD-CAR-1 in Heavily Pretreated CLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 4th 2024

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.
October 29th 2024

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens